RDHL
insider transactionsRedHill Biopharma Ltd. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-15.7M
0 buy · 15.7M sell
Net value · 90d
-$1.6K
$0 in · $1.6K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
1
0 buy · 15.7M sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Operating Officer
$0
30.8M sh
Own +68%
-
Sell·S
Chief Operating Officer
$1.6K
15.7M sh · $0.00
Own -6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 6, 2026 | Gilead Raday | Exercise M | 30.8M | $0 |
| Apr 6, 2026 | Gilead Raday | Sell S | 15.7M | $1.6K |
About RDHL insider trading
This page tracks insider transactions for RedHill Biopharma Ltd. (RDHL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.